文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

螺旋断层放疗对比三维适形放疗治疗高危前列腺癌:一项3期随机对照试验

Helical Tomotherapy Versus 3-Dimensional Conformal Radiation Therapy in High-Risk Prostate Cancer: A Phase 3 Randomized Controlled Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-07-14

这项3期随机对照试验将123例新诊断高危前列腺癌患者随机分入三维适形放疗组(60例)或螺旋断层放疗组(63例),两组均接受前列腺和盆腔淋巴结46 Gy/23次后前列腺追加32 Gy/16次放疗并联合3年辅助雄激素剥夺治疗。中位随访161个月,≥2级晚期直肠毒性发生率两组无显著差异(P=.83),≥2级晚期泌尿生殖毒性无显著差异(P=.17),生化进展或死亡风险无显著差异(HR 0.72,95%CI 0.46-1.15,P=.17)。

要点

  • 两组≥2级晚期直肠毒性分别为8.3%(三维适形组)和11.1%(断层放疗组),无显著差异(P=.83)。
  • 两组≥2级晚期泌尿生殖毒性分别为10.0%(三维适形组)和20.6%(断层放疗组),无显著差异(P=.17)。
  • 断层放疗组生化进展或死亡风险HR为0.72(95%CI 0.46-1.15,P=.17),无显著差异。

核心结论

  • 该3期试验中≥2级直肠毒性总体发生率低,且两组间无显著差异;螺旋断层放疗未显示生化无进展生存改善的显著证据。
  • 作者指出,鉴于样本量有限和事件率低,这些发现应考虑到可能存在II类错误。

研究设计与样本

  • 3期随机对照试验,新诊断高危前列腺癌患者随机接受三维适形放疗(60例)或螺旋断层放疗(63例),共123例。
  • 两组均接受前列腺和盆腔淋巴结初始剂量46 Gy/23次,随后前列腺追加32 Gy/16次,并联合3年辅助雄激素剥夺治疗。
  • 主要终点为晚期(放疗开始后>90天)直肠毒性,中位随访161个月。

主要发现

  • ≥2级晚期直肠毒性:三维适形组8.3%(95%CI 3.1-19.1,n=5) vs 断层放疗组11.1%(95%CI 5.0-22.2,n=7),组间无显著差异(P=.83)。
  • ≥2级晚期泌尿生殖毒性:三维适形组10.0%(95%CI 4.1-21.2) vs 断层放疗组20.6%(95%CI 11.9-33.0),无显著差异(P=.17)。
  • 生化进展或死亡风险:断层放疗组HR 0.72(95%CI 0.46-1.15,P=.17),两组间无显著差异。

关键数值与推荐

  • ≥2级晚期直肠毒性:三维适形组8.3%(95%CI 3.1-19.1,n=5) vs 断层放疗组11.1%(95%CI 5.0-22.2,n=7),P=.83。
  • ≥2级晚期泌尿生殖毒性:三维适形组10.0%(95%CI 4.1-21.2) vs 断层放疗组20.6%(95%CI 11.9-33.0),P=.17。
  • 生化进展或死亡风险:断层放疗组HR 0.72(95%CI 0.46-1.15),P=.17。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出,这些发现应考虑到样本量有限和事件率低可能导致II类错误。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We present long-term outcomes from a phase 3 randomized controlled trial that compared helical tomotherapy with 3-dimensional conformal radiation therapy (3D-CRT) in the treatment of high-risk prostate cancer. METHODS AND MATERIALS: Newly diagnosed patients with high-risk prostate cancer were randomly allocated to receive radical radiation therapy (RT) using 3D-CRT or helical tomotherapy. In both arms, patients received an initial dose of 46 Gy in 23 fractions to the prostate and pelvic lymph nodes, followed by an additional boost to the prostate of 32 Gy in 16 fractions. RT was combined with 3 years of adjuvant androgen deprivation. The primary endpoint was late (>90 days since RT initiation) rectal toxicity. RESULTS: Overall,123 patients were randomly assigned to either the 3D-CRT (n = 60) or tomotherapy (n = 63) arms. The median follow-up was 161 months. Overall, the proportion of patients with grade ≥ 2 late rectal toxicity was 8.3% (95% CI, 3.1-19.1; n = 5) in the 3D-CRT arm and 11.1% (95% CI, 5.0-22.2; n = 7) in the tomotherapy arm with no significant between-arm difference (P = .83). There was no significant difference (P = .17) in the proportion of patients with late grade ≥ 2 genitourinary toxicity:10.0% (95% CI, 4.1-21.2) in the 3D-CRT arm and 20.6% (95% CI, 11.9-33.0) in the tomotherapy arm. There was no significant difference in the hazard of biochemical progression or death between the 2 groups (hazard ratio for the tomotherapy arm: 0.72; 95% CI, 0.46-1.15; P = .17). CONCLUSIONS: In this phase 3 trial, the overall incidence of grade ≥ 2 rectal toxicity was low and was not significantly different between the 2 arms. There was no significant evidence of improved biochemical progression-free survival in patients treated with tomotherapy. These findings should be interpreted considering the possibility of type II errors due to limited sample size and low event rates.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Roy S, MacRae R, Grimes S, et al. Helical Tomotherapy Versus 3-Dimensional Conformal Radiation Therapy in High-Risk Prostate Cancer: A Phase 3 Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2024. PMID: 39009322. doi:10.1016/j.ijrobp.2024.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。